Sebela Pharmaceuticals
Sebela Pharmaceuticals is a U.S. pharmaceutical company with a market-leading position in Gastroenterology and a focus on innovation in Women’s Health.
Sebela Pharmaceuticals is a U.S. pharmaceutical company with a market-leading position in Gastroenterology and a focus on innovation in Women’s Health.
“The acquisition of Braintree is transformational for Sebela. It immediately propels the company into a market-leading position in one of our core therapeutic areas of Gastroenterology...” - Alan Cooke, CEO
Founded in 1983 in Braintree, Massachusetts, Braintree Laboratories has been committed to expanding the universe of colonoscopy preparation products for almost 40 years. Braintree is a specialty pharmaceutical company that develops, manufactures, and markets these products in the field of Gastroenterology.
In May 2018, Sebela Pharmaceuticals acquired Braintree Laboratories. It created a path for significant growth focusing on Sebela’s core therapeutic areas, including Gastroenterology and Women's Health.
Braintree, a part of Sebela Pharmaceuticals, is a market leader in Gastroenterology, including multiple marketed products, a rich
near-term pipeline of products for colorectal cancer screening, gastroesophageal reflux disease (GERD), and next-generation colonoscopy preps.
LEARN MORE ABOUT CRC SCREENING AND COLONOSCOPY >
“Building upon our market-leading position in colonoscopy
preparations, Sebela is well on the way to becoming the
leading GI pharma company.”
- Alan Cooke, CEO
Sebela Women’s Health focuses exclusively on the needs of women today, always with a vision to the future. We believe all women should have healthcare options that fit their individualized needs.
Through an extensive collaboration among clinicians, scientists, and pharmacologists, we’re using rigorous science, engineering, and pharmacology expertise to lead the way in innovation. We’re currently developing an innovative contraceptive platform that includes both hormonal and non-hormonal IUD options to address the needs of both patients and HCPs.
